Article reflects Companys leadership and innovation in scalable, reproducible manufacture of adeno-associated virus (AAV)-based gene therapies
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, announced that Sue Washer, President & Chief Executive Officer and Dave Knop, Vice President of Process Development, have been awarded first place in the BioProcess International (BPI) magazine inaugural Readers Choice Awards program, cell and gene therapies category, for their article, Viral-Vectored Gene Therapies: Harnessing Their Potential Through Scalable, Reproducible Manufacturing Processes.
High-productivity approaches to AAV manufacturing processes, like AGTCs HSV-helper based platform, will be crucial if we are to address the unmet clinical need growing across a variety of indications, said AGTC President and CEO, Sue Washer. There is no question that investing in the manufacturing process is imperative and our early commitment in this area has put AGTC in a strong position with respect to the purity and quality needed for late stage development and commercialization.
Concentrating on articles published from September 2019 through June 2020, and using rankings based on views, engagement, and download rates, BioProcess International identified the four most popular articles within each of its six pillars of bioprocessing coverage. The AGTC authors article received the highest number of votes from BPI readers, who ranked the nominees in terms of their innovativeness, presentability and applicability.
The eBook featuring the first-place article by Washer and Knop, as well as summarized versions of the second- and third-place articles, are available by visiting: https://bioprocessintl.com/wp-content/uploads/2020/11/18-11-eBook-RCA-CellGeneTherapies.pdf.
About AGTCAGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. The Companys most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its preclinical programs build on the Companys industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.
IR/PR CONTACTS:David Carey (IR) or Glenn Silver (PR)Lazar FINN PartnersT: (212) 867-1768 or (646) 871-8485david.carey@finnpartners.com or glenn.silver@finnpartners.com
Corporate Contact:Bill SullivanChief Financial OfficerApplied Genetic Technologies CorporationT: (617) 843-5728bsullivan@agtc.com
Stephen PotterChief Business OfficerApplied Genetic Technologies CorporationT: (617) 413-2754spotter@agtc.com
Read the rest here:
- Difference Between Ex Vivo and In Vivo Gene Therapy - December 30th, 2022 [December 30th, 2022]
- Gene therapy: The Potential for Treating Type 1 Diabetes - Healthline - December 30th, 2022 [December 30th, 2022]
- Gene therapy | Description, Uses, Examples, & Safety Issues - December 30th, 2022 [December 30th, 2022]
- Cell and gene therapy: Biopharma portfolio strategy | McKinsey - December 30th, 2022 [December 30th, 2022]
- History of Gene Therapy | Discovery and Evolution - December 30th, 2022 [December 30th, 2022]
- What is Gene Therapy? | FDA - U.S. Food and Drug Administration - December 30th, 2022 [December 30th, 2022]
- Gene Therapy Gel Offers New Hope Against Rare Blistering Disease - December 30th, 2022 [December 30th, 2022]
- Fact Check-mRNA vaccines are distinct from gene therapy ... - Reuters - December 6th, 2022 [December 6th, 2022]
- New Treatments for Retinitis Pigmentosa - American Academy of ... - December 6th, 2022 [December 6th, 2022]
- The Era of One-Shot, Multimillion-Dollar Genetic Cures Is Here - WIRED - December 6th, 2022 [December 6th, 2022]
- Greta Thunberg Says UN Climate Conference Is a Scam and She's Not Attending - November 4th, 2022 [November 4th, 2022]
- This Deepfake AI Singing Dolly Parton's "Jolene" Is Worryingly Good - November 4th, 2022 [November 4th, 2022]
- There's Something Strange About How These Stars Are Moving, Scientists Say - November 4th, 2022 [November 4th, 2022]
- Manslaughter Case Has a Strange Twist: Tesla That Killed Couple Was on Autopilot - November 4th, 2022 [November 4th, 2022]
- Twitter Working on Plan to Charge Users to Watch Videos - November 4th, 2022 [November 4th, 2022]
- China Plans to Send Monkeys to Space Station to Have Sex With Each Other - November 4th, 2022 [November 4th, 2022]
- Elon Musk Meeting With Advertisers, Begging Them Not to Leave Twitter - November 4th, 2022 [November 4th, 2022]
- NASA Sets Launch Date for Mission to $10 Quintillion Asteroid - November 4th, 2022 [November 4th, 2022]
- Scientists Found a Way to Control How High Mice Got on Cocaine - November 4th, 2022 [November 4th, 2022]
- Cats May Be Tampering With Crime Scenes, Scientists Say - November 4th, 2022 [November 4th, 2022]
- Scientists Use Actual Lunar Soil Sample to Create Rocket Fuel - November 4th, 2022 [November 4th, 2022]
- Scientists Spot "Stripped, Pulsating Core" of Star Caused By Horrific Accident - November 4th, 2022 [November 4th, 2022]
- US Gov to Crack Down on "Bossware" That Spies On Employees' Computers - November 4th, 2022 [November 4th, 2022]
- AOC Says Her Twitter Account Broke After She Made Fun of Elon Musk - November 4th, 2022 [November 4th, 2022]
- Hackers Just Took Down One of the World's Most Advanced Telescopes - November 4th, 2022 [November 4th, 2022]
- Huge Drone Swarm to Form Giant Advertisement Over NYC Skyline - November 4th, 2022 [November 4th, 2022]
- Chinese Spaceplane Releases Mystery Object Into Orbit - November 4th, 2022 [November 4th, 2022]
- That "Research" About How Smartphones Are Causing Deformed Human Bodies Is SEO Spam, You Idiots - November 4th, 2022 [November 4th, 2022]
- Jeff Bezos' Housekeeper Says She Had to Climb Out the Window to Use the Bathroom - November 4th, 2022 [November 4th, 2022]
- Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership - PR Newswire - October 19th, 2022 [October 19th, 2022]
- Gene therapy can make a real impact on global health but we need equitable access, say experts - World Economic Forum - October 19th, 2022 [October 19th, 2022]
- Gene Therapy Has Arrived. But So Will the $$$$$ Bills. | AMCP Nexus 2022 - Managed Healthcare Executive - October 19th, 2022 [October 19th, 2022]
- Carmine Gets Series A Funding to Develop Non-viral Gene Therapy |... - Cystic Fibrosis News Today - October 19th, 2022 [October 19th, 2022]
- FDA Expands Oversight of Cell and Gene Therapies - Pharmaceutical Technology Magazine - October 19th, 2022 [October 19th, 2022]
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 19th, 2022 [October 19th, 2022]
- Survey Reveals Most People with Spinal Muscular Atrophy Using New Gene Therapies, Focused on Treatment Pipeline - PR Newswire - October 19th, 2022 [October 19th, 2022]
- GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies - Yahoo Finance - October 19th, 2022 [October 19th, 2022]
- Gamma Biosciences, Lonza Enter Cell and Gene Therapy Alliance - Contract Pharma - October 19th, 2022 [October 19th, 2022]
- Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene... - October 19th, 2022 [October 19th, 2022]
- Gene therapy Luxturna now reimbursed in Quebec for people with previously untreatable inherited vision loss(1) - Canada NewsWire - October 19th, 2022 [October 19th, 2022]
- A sound approach for effective gene therapy delivery to brain - The Source - Washington University in St. Louis - Washington University in St. Louis - October 19th, 2022 [October 19th, 2022]
- Worldwide AAV Vector Industry Report 2022 - by Type of Therapy, Type of Gene Delivery Method Used, Target Therapeutic Area, Application Area, Scale of... - October 19th, 2022 [October 19th, 2022]
- LEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission - BioSpace - October 19th, 2022 [October 19th, 2022]
- Health News Roundup: Serum Institute to produce Ebola vaccine for use in Uganda outbreak; Eli Lilly to buy gene therapy company Akouos for $487... - October 19th, 2022 [October 19th, 2022]
- New Pittsburgh biomanufacturing center to accelerate cell and gene therapy innovation - BioPharma-Reporter.com - August 30th, 2022 [August 30th, 2022]
- Trinity team's new gene therapy shows promise for treating eye condition affecting millions across the globe - Ophthalmology Times - August 30th, 2022 [August 30th, 2022]
- Ovid turns to gene therapy startup to restock drug pipeline - BioPharma Dive - August 30th, 2022 [August 30th, 2022]
- Defining the Impact of Gene Therapy - Managed Healthcare Executive - August 30th, 2022 [August 30th, 2022]
- Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire - August 30th, 2022 [August 30th, 2022]
- India Gene Therapy Market Research Report 2022: Prospects, Trends, Market Size and Forecasts to 2028 - ResearchAndMarkets.com - Business Wire - August 30th, 2022 [August 30th, 2022]
- Global Cell and Gene Therapy Market to Surpass US$ 90,984.2 Million by 2030 - Coherent Market Insights - PR Newswire - August 30th, 2022 [August 30th, 2022]
- Walk Again Or Stop Blindness. How Gene Therapy Is Revolutionizing Medicine - Nation World News - August 30th, 2022 [August 30th, 2022]
- Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome - BioSpace - August 30th, 2022 [August 30th, 2022]
- Porton Advanced and Kun Tuo Announce Strategic Partnership to Deepen Gene and Cell Therapy CDMO and Clinical Research Services - PR Newswire - August 30th, 2022 [August 30th, 2022]
- Gene therapies for lung cancer identified by international team of scientists - Labiotech.eu - August 30th, 2022 [August 30th, 2022]
- BioForest is Breaking Out with Innovation, Talent and Investment - BioSpace - August 30th, 2022 [August 30th, 2022]
- Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio - Yahoo Finance - August 30th, 2022 [August 30th, 2022]
- An international team sets out to cure genetic heart diseases with one shot - Freethink - August 30th, 2022 [August 30th, 2022]
- What is the difference between sickle cells and healthy RBCs? - Medical News Today - August 30th, 2022 [August 30th, 2022]
- Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials - HDBuzz - August 30th, 2022 [August 30th, 2022]
- Cell therapy weekly: Kyverna Therapeutics appoints new Senior Vice President - RegMedNet - August 30th, 2022 [August 30th, 2022]
- GICELL Announces Research Collaboration with HK inno.N for next-generation CAR-NK therapy - BioSpace - August 30th, 2022 [August 30th, 2022]
- Document: Big Pharma exec: COVID shots are 'gene therapy' - July 8th, 2022 [July 8th, 2022]
- Gene & Cell Therapy FAQs | ASGCT - American Society of Gene & Cell ... - July 8th, 2022 [July 8th, 2022]
- Gene therapy - Mayo Clinic - July 8th, 2022 [July 8th, 2022]
- FDA approves novel gene therapy to treat patients with a rare form of ... - July 8th, 2022 [July 8th, 2022]
- Adeno-Associated Virus (AAV) as a Vector for Gene Therapy - July 8th, 2022 [July 8th, 2022]
- Gene therapy: Where the action is for retinal diseases - Modern Retina - July 8th, 2022 [July 8th, 2022]
- Adverum cuts jobs, restructures to give eye gene therapy another shot - BioPharma Dive - July 8th, 2022 [July 8th, 2022]
- EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNS - Labiotech.eu - July 8th, 2022 [July 8th, 2022]
- Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA - Business Wire - July 8th, 2022 [July 8th, 2022]
- TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022" - PR Newswire - July 8th, 2022 [July 8th, 2022]
- AAVIATE: Gene therapy via suprachoroidal drug delivery may lower treatment burden for patients with AMD - Modern Retina - July 8th, 2022 [July 8th, 2022]
- Gene Therapy Market is Expected to Grow Revenue up to USD 20 Billion by 2028 Know More with Infinium Global Research - Digital Journal - July 8th, 2022 [July 8th, 2022]
- Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week - The Motley Fool - July 8th, 2022 [July 8th, 2022]
- PROMISING STEM CELL THERAPY IN THE MANAGEMENT OF HIV & AIDS | BTT - Dove Medical Press - July 8th, 2022 [July 8th, 2022]
- Sio Gene Therapies Inc. (NASDAQ:SIOX) Short Interest Up 33.4% in June - Defense World - July 8th, 2022 [July 8th, 2022]
- Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy -... - July 8th, 2022 [July 8th, 2022]
- A look at prospects for the US gene therapy industry - BioPharma-Reporter.com - December 27th, 2021 [December 27th, 2021]
- Taysha Gene Therapies Added to the ICE Biotechnology Index - BioSpace - December 27th, 2021 [December 27th, 2021]